[{"orgOrder":0,"company":"Nutrasource","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Astaxanthin","moa":"NF-kappa-B inhibitor alpha","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Nutrasource","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nutrasource \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Nutrasource \/ Nutrasource"},{"orgOrder":0,"company":"Nutrasource","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Nutrasource","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nutrasource \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Nutrasource \/ Nutrasource"},{"orgOrder":0,"company":"Nutrasource","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Bacillus Subtilis ATCC 122264","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Nutrasource","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nutrasource \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Nutrasource \/ Nutrasource"},{"orgOrder":0,"company":"Nutrasource","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Potato Starch","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Nutrasource","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutrasource \/ Nutrasource","highestDevelopmentStatusID":"11","companyTruncated":"Nutrasource \/ Nutrasource"},{"orgOrder":0,"company":"Nutrasource","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"CAS 492-27-3","moa":"Glutamate receptor ionotropic, NMDA 1; Glutamate receptor ionotropic, NMDA 2B; Glutamate receptor ionotropic, NMDA 2A; Aryl hydrocarbon receptor; G-protein coupled receptor 35","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Nutrasource","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Cream","sponsorNew":"Nutrasource \/ Nutrasource","highestDevelopmentStatusID":"9","companyTruncated":"Nutrasource \/ Nutrasource"},{"orgOrder":0,"company":"Nutrasource","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Digestive Enzyme Blend","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Nutrasource","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutrasource \/ Nutrasource","highestDevelopmentStatusID":"8","companyTruncated":"Nutrasource \/ Nutrasource"},{"orgOrder":0,"company":"Nutrasource","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Nutrasource","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nutrasource \/ Nutrasource","highestDevelopmentStatusID":"6","companyTruncated":"Nutrasource \/ Nutrasource"},{"orgOrder":0,"company":"Nutrasource","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabinol","moa":"cannabinol derivatives","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Nutrasource","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutrasource \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Nutrasource \/ Nutrasource"},{"orgOrder":0,"company":"Nutrasource","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Bioplete","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Nutrasource","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutrasource \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Nutrasource \/ Nutrasource"},{"orgOrder":0,"company":"Nutrasource","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Nutrasource","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutrasource \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Nutrasource \/ Nutrasource"},{"orgOrder":0,"company":"Nutrasource","sponsor":"Bonafide Health","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"JDS-HF","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Nutrasource","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutrasource \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Nutrasource \/ Nutrasource"},{"orgOrder":0,"company":"Nutrasource","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Arrabina P Prebiotic","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Nutrasource","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutrasource \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Nutrasource \/ Nutrasource"},{"orgOrder":0,"company":"Nutrasource","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Ascorbic Acid","moa":"Collagen (CO)","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Nutrasource","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutrasource \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Nutrasource \/ Nutrasource"},{"orgOrder":0,"company":"Nutrasource","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Nutrasource","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutrasource \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Nutrasource \/ Nutrasource"},{"orgOrder":0,"company":"Nutrasource","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Inulinase","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Nutrasource","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutrasource \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Nutrasource \/ Nutrasource"},{"orgOrder":0,"company":"Nutrasource","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Alpha-GPC","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Nutrasource","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutrasource \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Nutrasource \/ Nutrasource"},{"orgOrder":0,"company":"Nutrasource","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Korean Red Ginseng Extract","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Nutrasource","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutrasource \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Nutrasource \/ Nutrasource"},{"orgOrder":0,"company":"Nutrasource","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"KH-1","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Nutrasource","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutrasource \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Nutrasource \/ Nutrasource"},{"orgOrder":0,"company":"Nutrasource","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"TPG1","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nutrasource","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutrasource \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Nutrasource \/ Nutrasource"},{"orgOrder":0,"company":"Nutrasource","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Cognizin","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Nutrasource","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutrasource \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Nutrasource \/ Nutrasource"},{"orgOrder":0,"company":"Nutrasource","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Collagen Peptide","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Nutrasource","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutrasource \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Nutrasource \/ Nutrasource"}]

Find Clinical Drug Pipeline Developments & Deals by Nutrasource

Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          April 29, 2025

                          Lead Product(s) : Potato Starch

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase IV

                          Recipient : MSP Starch Products Inc.

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          April 29, 2025

                          Lead Product(s) : Digestive Enzyme Blend

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase II

                          Recipient : Pancap Pharma Inc.

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          April 22, 2025

                          Lead Product(s) : Collagen Peptide

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Undisclosed

                          Recipient : Rousselot BVBA

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          April 02, 2025

                          Lead Product(s) : Cognizin

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Undisclosed

                          Recipient : Kirin Holdings Company, Limited

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          March 19, 2025

                          Lead Product(s) : Arrabina P Prebiotic

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Undisclosed

                          Recipient : Comet Bio Inc.

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 04, 2025

                          Lead Product(s) : CAS 492-27-3

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase II/ Phase III

                          Recipient : Birch BioMed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          January 28, 2025

                          Lead Product(s) : TPG1

                          Therapeutic Area : Immunology

                          Highest Development Status : Undisclosed

                          Recipient : Standard Process Inc.

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          August 29, 2024

                          Lead Product(s) : Cannabidiol

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Recipient : Royal DSM

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          June 24, 2024

                          Lead Product(s) : Ascorbic Acid

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Undisclosed

                          Recipient : Royal DSM

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          June 06, 2024

                          Lead Product(s) : KH-1

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Undisclosed

                          Recipient : Kalin Health, LLC

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank